PDF(Pubmed)
Abstract：
The emergence of malignant ascites (MA) indicates poor prognoses in patients with ovarian, gastrointestinal, breast, and pancreatic cancer. Interleukin-10 (IL-10) is a pleiotropic cytokine with immunoregulatory effects in tumor microenvironment. The level of IL-10 in MA varied across cancer types and patients, influencing cancer progression and outcomes. Originating from various immune and cancer cells, IL-10 contributes to complex signaling pathways in MA. Systemic IL-10 administration, although the evidence of its efficacy on MA is limited, still emerges as a promising therapeutic strategy because it can increase CD8+ T cells cytotoxicity and invigorate exhausted CD8+ tumor infiltration lymphocytes (TILs) directly. IL-10 signaling blockade also demonstrates great potential when combined with other immunotherapies in MA treatment. We reviewed the levels, origins, and functions of IL-10 in malignant ascites and overviewed the current IL-10 signaling targeting therapies, aiming to provide insights for MA treatment.
摘要：
恶性腹水（MA）的出现表明卵巢患者预后不良，胃肠,乳房,还有胰腺癌.白细胞介素-10（IL-10）是一种多效细胞因子，在肿瘤微环境中具有免疫调节作用。MA中IL-10的水平因癌症类型和患者而异，影响癌症进展和结果。起源于各种免疫和癌细胞，IL-10有助于MA中的复杂信号传导途径。全身IL-10给药，尽管其对MA疗效的证据有限，仍然是一种有前途的治疗策略，因为它可以增加CD8T细胞的细胞毒性并直接激活耗尽的CD8肿瘤浸润淋巴细胞（TIL）。IL-10信号传导阻断在MA治疗中与其他免疫疗法组合时也显示出巨大的潜力。我们审查了水平，起源,以及IL-10在恶性腹水中的功能，并概述了当前IL-10信号靶向治疗，旨在为MA治疗提供见解。
